Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that the U.S. Food and Drug Administration (FDA) ...
Infection with the fungus Candida parapsilosis is a major problem for individuals in intensive care units, as well as for premature infants and immunocompromised adults. Despite this, little is known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback